All companies
Visit website
General Genomics Inc.
OperatingFounded 2020
Accurately predict your risk of infectious disease (like COVID) and take control
Valuation cap ⓘ
$50.0M
As of May 2021 · from General Genomics SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$26,550
Across 1 round since 2021
Financials
FY2018–FY2023 · from SEC filings · hover any figure for its source$0
2018
$219K
−$526K
2019
$0
−$149K
2021
$8K
−$245K
2022
$441K
−$607K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$219,313
$0
$8,269
$440,579
Cost of goods sold
$0
$23,565
$0
$0
$0
Gross margin
—
89%
—
100%
100%
Net income
$0
-$526,180
-$149,393
-$245,162
-$606,779
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$158,806
$58,321
$223,086
$106,008
Accounts receivable
$0
$236,696
$231,908
$231,908
$371,866
Total assets
$0
$487,534
$364,344
$827,013
$1,336,650
Short-term debt
$0
$17,382
$0
$2,130
$4,300
Long-term debt
$0
$65,829
$0
$0
$0
Total liabilities
$0
$83,211
$0
$2,130
$4,300
Other
Headcount
—
6
—
5
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$50.0M
Valuation cap
General Genomics SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $26.6K / $1.1MInvestors 17Valuation cap $50M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 2 of 6 annual reports (FY2020–FY2025)
17 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001834175
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.